Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All colchicine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchColchicineColchicine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 23% Improvement Relative Risk ICU time 40% Colchicine  Valerio Pascua et al.  ICU PATIENTS Is very late treatment with colchicine + combined treatments beneficial for COVID-19? Retrospective 65 patients in multiple countries (Jun - Aug 2020) Shorter ICU admission with colchicine + combined treatments (p=0.03) c19early.org Valerio Pascua et al., PLOS ONE, January 2021 Favors colchicine Favors control

A multi-mechanism approach reduces length of stay in the ICU for severe COVID-19 patients

Valerio Pascua et al., PLOS ONE, doi:10.1371/journal.pone.0245025
Jan 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Colchicine for COVID-19
6th treatment shown to reduce risk in September 2020
 
*, now known with p = 0.00000056 from 50 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19early.org
Retrospective 65 ICU patients in the USA and Honduras, showing shorter ICU stay with combined treatment including colchicine, LMWH, tocilizumab, dexamethasone, and methylprednisolone.
risk of death, 22.8% lower, RR 0.77, p = 0.60, treatment 5 of 35 (14.3%), control 12 of 30 (40.0%), NNT 3.9, adjusted per study, odds ratio converted to relative risk, multivariable.
ICU time, 39.9% lower, relative time 0.60, p = 0.03, treatment 35, control 30, adjusted per study, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Valerio Pascua et al., 7 Jan 2021, retrospective, multiple countries, peer-reviewed, 19 authors, study period 10 June, 2020 - 6 August, 2020, average treatment delay 6.1 days, dosage 1.5mg day 1, 1mg days 2-5, varied by location, this trial uses multiple treatments in the treatment arm (combined with LMWH, tocilizumab, dexamethasone, methylprednisolone) - results of individual treatments may vary.
This PaperColchicineAll
A multi-mechanism approach reduces length of stay in the ICU for severe COVID-19 patients
Fernando Valerio Pascua, Oscar Diaz, Rina Medina, Brian Contreras, Jeff Mistroff, Daniel Espinosa, Anupamjeet Sekhon, Diego Paz Handal, Estela Pineda, Miguel Vargas Pineda, Hector Pineda, Maribel Diaz, Anita S Lewis, Heike Hesse, Miriams T Castro Lainez, Mark L Stevens, Miguel Sierra- Hoffman, Sidney C Ontai, Vincent Vanburen
PLOS ONE, doi:10.1371/journal.pone.0245025
Purpose COVID-19 pandemic has multifaceted presentations with rising evidence of immune-mediated mechanisms underplay. We sought to explore the outcomes of severe COVID-19 patients treated with a multi-mechanism approach (MMA) in addition to standard-of-care (SC) versus patients who only received SC treatment. Materials and methods Data were collected retrospectively for patients admitted to the intensive care unit (ICU). This observational cohort study was performed at five institutions, 3 in the United States and 2 in Honduras. Patients were stratified for MMA vs. SC treatment during ICU stay. MMA treatment consists of widely available medications started immediately upon hospitalization. These interventions target immunomodulation, anticoagulation, viral suppression, and oxygenation. Primary outcomes included in-hospital mortality and length of stay (LOS) for the index hospitalization and were measured using logistic regression.
References
Alam, Hobbelink, Van Tienhoven, Van De Ven, Jansma et al., The impact of the use of the Early Warning Score (EWS) on patient outcomes: a systematic review, Resuscitation, doi:10.1016/j.resuscitation.2014.01.013
Beigel, Tomashek, Dodd, Mehta, Zingman et al., Remdesivir for the Treatment of Covid-19-Preliminary Report, N Engl J Med
Cao, Li, COVID-19: towards understanding of pathogenesis, Cell Res, doi:10.1038/s41422-020-0327-4
Chao, Woo, Hospitals pushed to the brink in Wuhan: 'I just want to save his life, Wall Street Journal
Cummings, Baldwin, Abrams, Jacobson, Meyer et al., Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study, Lancet, doi:10.1016/S0140-6736%2820%2931189-2
Dasta, Mclaughlin, Mody, Piech, Daily cost of an intensive care unit day: the contribution of mechanical ventilation, Crit Care Med, doi:10.1097/01.ccm.0000164543.14619.00
De Wit, Van Doremalen, Falzarano, Munster, SARS and MERS: recent insights into emerging coronaviruses, Nat Rev Microbiol, doi:10.1038/nrmicro.2016.81
Deftereos, Giannopoulos, Vrachatis, Siasos, Giotaki et al., GRECCO-19 investigators. Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial, JAMA Netw Open, doi:10.1001/jamanetworkopen.2020.13136
Despres, Brunin, Berthier, Pili-Floury, Besch, Prone positioning combined with high-flow nasal or conventional oxygen therapy in severe Covid-19 patients, Crit Care, doi:10.1186/s13054-020-03001-6
Edgar, Najmabadi, Platoff, Texas hospitals are running out of drugs, beds, ventilators and even staff, Texas Tribune
Elharrar, Trigui, Dols, Touchon, Martinez et al., Use of Prone Positioning in Nonintubated Patients With COVID-19 and Hypoxemic Acute Respiratory Failure, JAMA, doi:10.1001/jama.2020.8255
Finkelsztein, Jones, Ma, Pabo ´n, Delgado et al., Comparison of qSOFA and SIRS for predicting adverse outcomes of patients with suspicion of sepsis outside the intensive care unit, Crit Care, doi:10.1186/s13054-017-1658-5
Fox, Akmatbekov, Harbert, Li, Brown et al., Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans, Lancet Respir Med, doi:10.1016/S2213-2600%2820%2930243-5
Helms, Tacquard, Severac, Leonard-Lorant, Ohana et al., High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study, Intensive Care Med, doi:10.1007/s00134-020-06062-x
Kewan, Covut, Mj, Rose, Gopalakrishna et al., Tocilizumab for treatment of patients with severe COVID-19: A retrospective cohort study, EClinicalMedicine, doi:10.1016/j.eclinm.2020.100418
Mafham, COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England, Lancet, doi:10.1016/S0140-6736%2820%2931356-8
Rosa, Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era, Eur Heart J, doi:10.1093/eurheartj/ehaa409
Rothan, Byrareddy, The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak, J Autoimmun, doi:10.1016/j.jaut.2020.102433
Sabatino, Impact of cardiovascular risk profile on COVID-19 outcome. A meta-analysis, PLoS One, doi:10.1371/journal.pone.0237131
Sanche, Lin, Xu, Romero-Severson, Hengartner et al., High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2, Emerg Infect Dis, doi:10.3201/eid2607.200282
Semple, In some nations, coronavirus is only one of many outbreaks
Soy, Keser, ¨ndu ¨z, Tabak, ¨ndu ¨z et al., Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment, Clin Rheumatol, doi:10.1007/s10067-020-05190-5
Tang, Bai, Chen, Gong, Li et al., Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy, J Thromb Haemost, doi:10.1111/jth.14817
Toniati, Piva, Cattalini, Garrafa, Regola et al., Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy, Autoimmun Rev, doi:10.1016/j.autrev.2020.102568
Valerio Pascua, Diaz, Medina, Contreras, Mistroff et al., Project administration: Fernando Valerio Pascua
Valerio Pascua, Diaz, Medina, Contreras, Mistroff et al., Vincent
Villar, Confalonieri, Pastores, Meduri, Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019, Crit Care Explor
Wang, Zhang, Du, Du, Zhao et al., Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet, doi:10.1016/S0140-6736%2820%2931022-9
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, doi:10.1016/S0140-6736%2820%2930566-3
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit